Explore Currently Enrolling Genentech and Roche Clinical Trials in Oncology

Search for clinical trials by making selections below.

Tumor Type View All

Breast Gastrointestinal Genitourinary Gynecologic Hematology Lung Melanoma Solid Tumor

Phase

III II I

Molecule*

Select...
Antibody-drug conjugate (RG6109) Antibody-drug conjugate (RG6148) Anti-MUC16 TDC (RG7882) Anti-TIGIT MAb (MTIG7192A, RG6058) Atezolizumab (anti-PDL1 MAb) (RG7446) BET inhibitor (TEN-010, RG6146) Bevacizumab (anti-VEGF Mab) CD20 TCB (RG6026) CD20 TDB (RG7828) CEA TCB (RG7802) Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ChK1 inhibitor (GDC-0575, RG7741) Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) Codrituzumab (anti–glypican-3 MAb) (GC33, RG7686) Emactuzumab (anti–CSF-1R MAb) (RG7155) Entrectinib FAP-DR5 biMAb (RG7386) FAP-IL2v FP (RG7461) Glypican-3/CD3 biMAb (CHU) Idasanutlin (MDM2 antagonist) (RG7388) Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) Monoclonal antibody (RG6160) Monoclonal antibody (RG6194) Obinutuzumab Pan-RAF inhibitor (RG6185) Personalized cancer vaccine (RG6180) PI3K inhibitor (GDC-0077, RG6114) Polatuzumab vedotin (anti-CD79b ADC) (RG7596) Raf/MEK dual inhibitor Selective estrogen receptor degrader (SERD[3]) (GDC-9545, RG6171) Selicrelumab (anti-CD40 MAb) (RG7876) Taselisib (PI3K inhibitor) (GDC-0032, RG7604) Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601)

US Region

International

Region

Select...
Clear All
View Results
Expand +

Tumor Type: Genitourinary

Phase: PHASE III, PHASE II, PHASE I

Region:

Molecule:

For more information about recruiting clinical trials, please call the Trial Information Support Line for US Clinical Trial information at 888-662-6728 or visit ClinicalTrials.gov.
Email your search results to yourself.
Clear All
View Results
Tumor Type Phase Molecule* Location Study Contact
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AR NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AR
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AR NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AR
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AT NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AT
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AT NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AT
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AU NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AU
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AU NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AU
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AU NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AU
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AU NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AU
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AZ NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AZ
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AZ NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) AZ
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BA NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BA
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BE NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BE
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BE NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BE
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BE NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BE
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BE NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BE
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BR NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BR
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BR NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) BR
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CH NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CH
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CL NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CL
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CL NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CL
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CN NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CN
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CN NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CN
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CN NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CN
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CN NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CN
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CO NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CO
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CO NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CO
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CO NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CO
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CT NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CT
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CT NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) CT
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DE NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DE
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DE NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DE
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DE NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DE
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DE NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DE
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DK NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DK
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DK NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) DK
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) EE NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) EE
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FI NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FI
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FI NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FI
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FL NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FL
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FL NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FL
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FL NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FL
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FL NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FL
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FR NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FR
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FR NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FR
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FR NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) FR
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GA NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GA
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GB NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GB
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GB NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GB
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GB NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GB
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GB NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GB
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GR NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GR
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GR NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) GR
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) HK NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) HK
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) HU NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) HU
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IA NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IA
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IE NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IE
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IN NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IN
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IN NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IN
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IT NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IT
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IT NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IT
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IT NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IT
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IT NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) IT
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) JP NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) JP
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) JP NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) JP
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) JP NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) JP
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) JP NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) JP
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KR NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KR
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KR NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KR
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KR NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KR
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KS NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KS
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KS NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KS
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KY NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KY
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KY NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) KY
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) LA NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) LA
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) LA NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) LA
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MA NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MA
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MA NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MA
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MD NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MD
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MD NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MD
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ME NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ME
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MI NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MI
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MI NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MI
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MN NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MN
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MN NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MN
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MN NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MN
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MO NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MO
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MS NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MS
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MX NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MX
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MY NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) MY
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NA NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NA
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NA NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NA
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NC NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NC
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NC NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NC
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NC NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NC
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NE NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NE
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NJ NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NJ
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NJ NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NJ
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NJ NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NJ
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NJ NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NJ
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NL NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NL
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NL NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NL
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NL NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NL
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NV NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NV
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NV NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NV
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OH NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OH
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OH NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OH
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OH NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OH
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OK NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) OK
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PA NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PA
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PA NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PA
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PA NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PA
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PL NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PL
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PL NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PL
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PL NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PL
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PL NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PL
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PT NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) PT
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RI NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RI
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RO NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RO
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RS NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RS
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RS NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RS
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RU NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RU
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RU NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RU
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RU NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RU
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RU NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) RU
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SC NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SC
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SC NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SC
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SC NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SC
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SD NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SD
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SG NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) SG
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TH NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TH
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TH NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TH
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TN NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TN
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TN NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TN
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TR NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TR
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TR NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TR
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TR NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TR
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TW NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TW
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TW NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TW
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TW NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TW
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TW NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TW
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TX NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TX
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TX NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) TX
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) UA NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) UA
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) UA NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) UA
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) UA NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) UA
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) UT NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) UT
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) VA NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) VA
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) VA NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) VA
NCT03016312—A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) WA NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) WA
NCT02450331—A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) WV NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) WV
NCT03024996—A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Tumor
Type
Phase Molecule* Location
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ZA NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Genitourinary III Atezolizumab (anti-PDL1 MAb) (RG7446) ZA
NCT02807636—Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) AT NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) AT
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) AU NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) AU
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) AZ NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) AZ
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) BE NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) BE
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) BR NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) BR
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) CA NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) CA
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) CA NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) CA
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) CN NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) CN
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) CR NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) CR
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) CT NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) CT
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) DC NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) DC
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) DK NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) DK
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) ES NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) ES
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) FL NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) FL
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) FR NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) FR
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) GA NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) GA
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) GB NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) GB
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) GR NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) GR
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) HU NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) HU
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) IE NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) IE
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) IL NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) IL
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) IL NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) IL
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) IT NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) IT
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) JP NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) JP
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) KR NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) KR
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) MA NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) MA
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) MD NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) MD
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) MI NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) MI
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) MO NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) MO
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) MX NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) MX
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) NO NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) NO
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) OH NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) OH
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) OR NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) OR
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) PA NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) PA
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) PL NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) PL
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) PT NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) PT
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) RI NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) RI
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) RU NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) RU
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) SC NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) SC
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) TH NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) TH
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) TW NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) TW
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) TX NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) TX
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT03093922—A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT03093922—A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446) NJ NCT03093922—A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446) NJ
NCT03093922—A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT03093922—A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT03093922—A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab) MA NCT02724878—Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Genitourinary II Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab) MA
NCT02724878—Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib AL NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib AL
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib AU NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib AU
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib AZ NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib AZ
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib BE NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib BE
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib CA NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib CA
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib CO NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib CO
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib CT NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib CT
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib DC NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib DC
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib DE NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib DE
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib ES NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib ES
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib FL NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib FL
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib FR NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib FR
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib GA NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib GA
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib GB NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib GB
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib HI NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib HI
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib HK NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib HK
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib IL NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib IL
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib IN NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib IN
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib IT NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib IT
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib JP NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib JP
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib KR NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib KR
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib LA NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib LA
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib MA NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib MA
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib MI NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib MI
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib MN NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib MN
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib MO NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib MO
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib NC NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib NC
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib NH NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib NH
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib NL NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib NL
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib NV NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib NV
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib NY NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib NY
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib OH NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib OH
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib OK NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib OK
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib OR NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib OR
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib PA NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib PA
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib PL NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib PL
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib SG NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib SG
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib TW NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib TW
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib TX NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib TX
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib UT NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib UT
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib VA NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib VA
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib WA NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib WA
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II Entrectinib WI NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Genitourinary II Entrectinib WI
NCT02568267—Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) AL NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) AL
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) IA NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) IA
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) MD NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) MD
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) NC NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) NC
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02989584—A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02989584—A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) OH NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) OH
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) OK NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) OK
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) OR NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Genitourinary II, I Atezolizumab (anti-PDL1 MAb) (RG7446) OR
NCT02792192—Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) AU NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) AU
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) AZ NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) AZ
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CO NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CO
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CT NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CT
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CT NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) CT
NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) DC NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) DC
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) DC NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) DC
NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) FL NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) FL
NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) GA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) GA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) HI NCT03024216—Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) HI
NCT03024216—Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) IN NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) IN
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) IN NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) IN
NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) LA NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) LA
NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) MD NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) MD
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) MI NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) MI
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) MI NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) MI
NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) MN NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) MN
NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) MO NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) MO
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) NC NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) NC
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) NC NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) NC
NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) NE NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) NE
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) OH NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) OH
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) PA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) PA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) PA NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) PA
NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) TN NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) TN
NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) TX NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) TX
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) WA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) WA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) WA NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) WA
NCT02814669—Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) WI NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446) WI
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) CA NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) CA
NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) DK NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) DK
NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) ES NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) ES
NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) FR NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) FR
NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) GB NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) GB
NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) IL NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) IL
NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) IT NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) IT
NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) KR NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) KR
NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) MD NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), FAP-IL2v FP (RG7461) MD
NCT03063762—Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) AZ NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) AZ
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) GB NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) GB
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NY NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NY
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) OR NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) OR
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genitourinary I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
1 of 325 clinical trials
1-4 of 325 clinical trials
ClickTap on the NCT numbers above to visit ClinicalTrials.gov for further details about each trial, including eligibility criteria, primary and secondary outcome measures, and contacts and locations.
This website is intended for US healthcare professionals and contains information on investigational compounds and drug uses that have not been approved by the FDA. Click "OK" if you are a healthcare professional and wish to proceed.
CancelOK
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
CancelContinue
The list of international studies is not comprehensive; only international studies that also include actively enrolling US sites are listed.

Click "OK" if you wish to proceed.
CancelOK